Benítez-Agudelo JC, Barceló-Martínez E, Gelves-Ospina M, Díaz-Bernier A, Orozco-Acosta E

Language: Spanish
References: 16
Page: 39-50
PDF size: 417.76 Kb.

ABSTRACT

Introduction: Diabetes mellitus is the most prevalent metabolic disease worldwide. “Adherence to treatment” is critical in the metabolic control of it and described as the action actively and voluntarily engages in the management of the disease.
Objective: To determine the influence of neuropsychological and psychological variables in adherence to treatment of patients with type 2 diabetes.
Methods: 60 subjects were evaluated: 30 with controlled diabetes (DC) and 30 with uncontrolled diabetes (DNC), submitted by centers-diabetes in the city of Barranquilla, between July and November 2015, to which underwent neuropsychological assessment, perception of health (general health questionnaire Goldberg, GHQ-28) and adherence to treatment (scale adherence treatment of type II Diabetes Mellitus: EATDMIII). The methodological approach was transversal descriptive, casecontrol analysis, selection of the sample was not probabilistic intentional. U test of Mann-Whitney and linear regression model was used to perform the analysis.
Results: We observed significant commitment of attention, memory and executive functions in patients with DNC. We found a significant difference between the two groups in scores on the scale (EATDMIII), in: exercise, hygiene and selfcare, diet and fitness assessment. It was identified that anxiety-insomnia variable has a risk of 0.771 (p=0.035), which may influence adherence to treatment.
Conclusions: Factors such as physical exercise, hygiene and self-care, diet and fitness assessment are fundamental in metabolic control these patients. Similarly, psychological variables (anxiety-insomnia) are determining adherence to treatment in this group of patients, which; being potentially modifiable they must be considered and controlled early in any therapeutic regimen.

REFERENCES

1. Organización mundial de la salud. Global data on visual impairments. Geneva: OMS; 2015. World Health Organization.

2. Organización mundial de la salud. Informe mundial sobre la diabetes, perfiles de los países para la diabetes. Geneva: OMS; 2016. World Health Organization.

3. Pozzilli P, David Leslie R, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician’s personalized approach. Diabetes/ metabolism research and reviews 2010; 26: 239-244.

4. Villalobos PA, Quiros MD, Sanabria LG, Brenes SJ. Factores involucrados en la adhesión al tratamiento de la diabetes mellitus tipo II en una muestra de pacientes diabéticos de la zona norte de Costa Rica: un estudio psicométrico. Revista Diversitas Perspectivas en psicología. Universidad Catolica de Costa Rica. 2006; pp. 27.

5. Figueroa CL, Gamarra G. Factores asociados con no control metabólico en diabéticos pertenecientes a un programa de riesgo cardiovascular. Acta Médica Colombiana 2013; 38: 213- 221.

6. Zapata M, Herrera J, Puerta I, Romero M, Arango C, Barceló E, Zapata L, Ramírez A. Estandarización de pruebas neurocognitivas en sujetos normales colombianos. [Trabajo de Investigación, convocatoria interna]. Medellín: Universidad San buenaventura. 2007.

7. Cervantes-Arriaga A, Calleja-Castillo J, Rodríguez-Violante M. Función cognitiva y factores cardiometabólicos en diabetes mellitus tipo 2. Medicina Interna de México 2009; 25.

8. Last David, et. al. “Global and regional effects of type 2 diabetes on brain tissue volumes and cerebral vasoreactivity.” Diabetes care 2007: 30: 1193-1199.

9. Gómez Muñoz N. Alteraciones neuropsicológicas asociadas a la diabetes mellitus 2 (dm2) ya sus factores de riesgo en población antioqueña. Medellin (Colombia); 2011.

10. Villa GIC, Zuluaga Arboleda C, Restrepo Roldán LF. Propiedades psicométricas del cuestionario de salud general de Goldberg GHQ-12 en una institución hospitalaria de la ciudad de Medellin. Avances en psicología latinoamerica 2013; 31: 532-545.

11. LAURO, José. Alteraciones emocionales en pacientes diabéticos con nefropatía. Rev Med IMSS 2004; 42: 379-385.

12. Quirós-Morales D, Villalobos-Pérez A. Comparación de factores vinculados a la adherencia al tratamiento en Diabetes Mellitus tipo II entre una muestra urbana y otra rural de Costa Rica. Universitas Psychologica 2007; 6: 679-688.

13. Sánchez YE.Modelos de cognición social y adherencia terapéutica en pacientes con cáncer. Avances en Psicología Latino Americana/Bogotá (Colombia) 2007; 25: 7-21.

14. Poncelas AR. Deterioro de las funciones ejecutivas en los pacientes diabéticos. Alzheimer. Real Invest Demenc 2012; 56: 37-42.

15. Maté J, Hollenstein MF, Gil FL. Insomnio, ansiedad y depresión en el paciente oncológico. Psicooncología 2004; 1: 211-230.

16. Garza AQ. Intervención telefónica para promover la adherencia terapéutica en pacientes diabéticos con síntomas de ansiedad y depresión. Enseñanza e Investigación en Psicología 2012; 17: 387-403.